enquiry@pharmascroll.com
Mail Us
-
Recent MS survey, sponsored by Celgene, highlights useful patient insights
- October 16, 2018
- Posted by: Pharmascroll
No CommentsA survey from the Multiple Sclerosis Association of America (MSAA), sponsored by Celgene, showed people with multiple sclerosis are worried about brain volume loss and want more information. About Pharmascroll: Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease
-
Further evidence generated for Neurofilament light chain as MS biomarker
- September 7, 2018
- Posted by: Pharmascroll
As per a latest study results published in Dove Press, further clinical evidence has been generated to support the use of Neurofilament light chain as a biomarker for Multiple Sclerosis patients. There is a need for biomarkers in multiple sclerosis (MS) to make an early diagnosis and monitor its progression. This study was designed to
-
Ibudilast shows benefits on slowing brain shrinkage in the latest trial results
- September 6, 2018
- Posted by: Pharmascroll
MediciNova announced that the New England Journal of Medicine has published results of the SPRINT-MS Phase 2b trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS). “These findings are significant for patients with progressive MS,” says Robert Fox, M.D., the study’s principal investigator and vice-chair for research in Cleveland Clinic’s Neurological Institute. “Our hope
-
New form of Multiple Sclerosis, MCMS, identified by investigators
- August 23, 2018
- Posted by: Pharmascroll
As per a new research published in The Lancet, Investigators at the Cleveland Clinic have identified a novel form of Multiple Sclerosis (MS) called myelocortical MS (MCMS). This novel form of MS differs from the traditional forms in terms of its effect on patients’ brains. Demyelination of cerebral white matter is thought to drive neuronal degeneration
-
Multiple Sclerosis patients taking IV treatment mostly satisfied, claims study
- August 20, 2018
- Posted by: Pharmascroll
As per a new study, conducted on a limited number of patients, patients have shown high level of satisfaction from the current IV treatment conditions. Multiple sclerosis (MS) treatment aims not only to prevent the rate of relapse, but also to slow down patient’s disability progression. Monoclonal antibodies constitute a new class of therapeutic agents
-
TG Therapeutics completes Enrollment for Ublituximab in MS trial
- August 12, 2018
- Posted by: Pharmascroll
TG Therapeutics announced that target enrollment in the ULTIMATE I and II Phase 3 trials has been achieved. ULTIMATE I and II are two independent Phase 3 clinical trials evaluating the safety and efficacy of ublituximab (TG-1101), the Company’s glycoengineered anti-CD20 monoclonal antibody, as compared to teriflunomide, in patients with relapsing forms of Multiple Sclerosis
-
Botox shows efficacy in Multiple Sclerosis urinary symptoms
- August 10, 2018
- Posted by: Pharmascroll
As per a recent study conducted and published in Neurology, onabotulinumtoxinA (Botox) has shown efficacy in improving urinary symptoms in MS patients. The study was conducted with an aim to evaluate the efficacy and safety of onabotulinumtoxinA 100 U in noncatheterizing patients with multiple sclerosis (MS) with urinary incontinence (UI) due to neurogenic detrusor overactivity
-
Sanofi launches multiple sclerosis drug Aubagio in India
- August 7, 2018
- Posted by: Pharmascroll
As per an article published in Hindu Business Line, Drug firm Sanofi today said its specialty care global business unit Sanofi Genzyme has launched its multiple sclerosis treatment drug Aubagio in India. The drug offers patients diagnosed with multiple sclerosis the efficacy and convenience of once-a-day oral treatment, Sanofi Genzyme said in a statement. Commenting
-
New Biomarkers identified for Progressive Multiple Sclerosis
- July 8, 2018
- Posted by: Pharmascroll
As per a recent article published in “The American Journal of Managed Care”, two recent studies, which were also presented at the 4th Congress of the European Academy of Neurology, examined the different effects and aspects of progressive multiple sclerosis (MS). One study aimed to investigate the contribution of the spinal cord area and brain
-
Pre-clinical data for EHP-101 in Multiple Sclerosis, presented by Emerald
- July 5, 2018
- Posted by: Pharmascroll
Emerald Health Pharmaceuticals Inc. (EHP presented preclinical data for its lead drug product candidate, EHP-101, at the 28th Annual Symposium of the International Cannabinoid Research Society (ICRS). EHP-101 is based on a patented synthetic cannabidiol (CBD)-derived new chemical entity (NCE) that is initially being developed for multiple sclerosis (MS) and scleroderma (SSc). Novel data were